Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD
Saved in:
| Main Authors: | Mia Jensen, Steffen F. Nielsen, Steffen Thiel, Søren W.K. Hansen, Yaseelan Palarasah, Per Svenningsen, Jesper N. Bech, Frank H. Mose, Boye L. Jensen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924020357 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Community series in the role of complement in health and disease, volume II
by: Maciej Cedzyński, et al.
Published: (2025-07-01) -
Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin
by: Steffen Flindt Nielsen, et al.
Published: (2025-01-01) -
<i>Echinococcus multilocularis</i> Calreticulin Inhibits Lectin Pathway of Complement Activation by Directly Binding to Mannose-Binding Lectin
by: Yuxiao Shao, et al.
Published: (2025-04-01) -
Complement levels and their diagnostic utility in neonatal sepsis
by: Fuqiang Diao, et al.
Published: (2025-05-01) -
Rationale for targeting complement in COVID‐19
by: Anastasia Polycarpou, et al.
Published: (2020-07-01)